{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-266741","form_type":"8-K","ticker":"RGEN","cik":"0000730272","company_name":"REPLIGEN CORP","filed_at":"2023-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.853559+00:00","generated_at":"2026-06-09T05:09:33.946684+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Repligen Q3 revenue $141.2M (-30% YoY); narrows FY2023 outlook, sees order recovery","bullets":["Total revenue $141.2M, base business $140.1M; GAAP EPS $0.32, adjusted EPS $0.23.","Book-to-bill ratio of 1.07; orders strengthened, especially from Pharma customers.","Narrows FY2023 revenue guidance to $635-645M (prev. $635-665M); lowers adj. operating margin to 15-16%.","Restructuring charges of $24M in operating income; acquired Metenova AB on Oct 2 for $164M cash + $9M equity."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-266741","json":"https://secwatch.observer/filing/0001193125-23-266741.json","markdown":"https://secwatch.observer/filing/0001193125-23-266741.md","text":"https://secwatch.observer/filing/0001193125-23-266741.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/730272/000119312523266741/0001193125-23-266741-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/730272/000119312523266741/d510261d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T05:09:33.946684+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"49e28f7643a2877be10cf126d2191fe177bc4054","claim":"REPLIGEN CORP reported fiscal year 2023 results: revenue $635M-$645M, net income $72M-$75M, EPS $1.26-$1.32. Guidance lowered.","evidence_excerpt":"Our financial guidance for the fiscal year 2023 is based on expectations for our existing business. Our GAAP and Adjusted (non-GAAP) guidance includes the impact of our FlexBiosys and Metenova acquisitions and excludes the impact of potential additional acquisitions, and future fluctuations in foreign currency exchange rates. CURRENT GUIDANCE (at October 31, 2023) PRIOR GUIDANCE (at August 2, 2023) FY 2023 GAAP Adjusted (Non-GAAP) GAAP Adjusted (Non-GAAP) Total Reported Revenue $635M-$645M $635M-$645M $635M-$665M $635M-$665M","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/730272/000119312523266741/0001193125-23-266741-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2023"},{"label":"Revenue","value":"$635M-$645M"},{"label":"Net income","value":"$72M-$75M"},{"label":"EPS","value":"$1.26-$1.32"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"712d696e8a0cd2fc201c70b4a988c3a65e4057af","claim":"REPLIGEN CORP reported third quarter ended September 30, 2023 results: revenue $141.2 million, net income $18.2 million, EPS $0.32.","evidence_excerpt":"100 Waltham, Massachusetts 02453 Repligen Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Guidance • Reports total third quarter revenues of $141.2 million, with base business revenues of $140.1 million • Orders strengthened with total book-to-bill ratio of 1.07 • Narrows full year revenue guidance to range of $635-$645 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/730272/000119312523266741/0001193125-23-266741-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$141.2 million"},{"label":"Net income","value":"$18.2 million"},{"label":"EPS","value":"$0.32"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}